Ciprofloxacin Prescribing Patterns in a Paediatric Department: A Two-Year Retrospective Audit

Background: Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic associated with a significant adverse effect profile, including musculoskeletal toxicity, tendinopathy, and serious neurological reactions. In paediatric populations, the additional risks of arthropathy and clinically significant drug interactions, including with aminophylline and methotrexate, further restrict its appropriate use. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued yellow card warnings advising that ciprofloxacin should only be prescribed when no suitable alternative exists. Despite this, fluoroquinolones remain among the most widely prescribed antibiotic classes globally. This audit examined ciprofloxacin prescribing patterns across the paediatric departments of Royal Devon University Healthcare NHS Foundation Trust (RDUH) to assess prescribing frequency, indication appropriateness, and regional variation, with the aim of identifying opportunities to reduce unnecessary use in line with antimicrobial stewardship principles.

Methods: A retrospective audit of ciprofloxacin prescriptions was conducted across both RDUH paediatric departments — Royal Devon and Exeter Hospital (RDE) and North Devon District Hospital (NDDH) — covering January 2023 to December 2024. Prescribing data were extracted from electronic prescribing records and each prescription was reviewed by site and clinical indication. Prescribing was assessed against MHRA fluoroquinolone guidance, which advises restricting use to situations where no suitable alternative exists.

Results: A total of 94 ciprofloxacin prescriptions were identified. RDE accounted for 66 prescriptions (70%) and NDDH for 28 (30%). This inter-site difference likely reflects the greater patient volume and clinical complexity at RDE, which hosts a dedicated CF service; however, differences in prescribing culture between the two sites cannot be excluded. Overall, ciprofloxacin use decreased across both sites over the two-year period, representing an encouraging trend.

The leading indication was CF exacerbation, accounting for 19 prescriptions (20% of total). Ciprofloxacin is commonly used in CF exacerbations given its activity against Pseudomonas aeruginosa and its oral bioavailability, though intravenous beta-lactams combined with aminoglycosides remain established alternatives. Urinary tract infections (UTIs) accounted for 12 prescriptions (13%) and respiratory tract infections (RTIs) for 9 (10%), with both indications concentrated almost exclusively in RDE. Additional indications included epididymitis, epididymo-orchitis, bronchiectasis, and surgical prophylaxis. Prescribing for UTIs and RTIs is of particular concern, as MHRA guidance does not support fluoroquinolone use in these contexts when effective alternatives exist.

Conclusion: This audit demonstrates substantial ciprofloxacin prescribing across RDUH paediatric services, with a pattern of use in conditions where safer alternatives are available. Regional variation suggests inconsistency in antimicrobial stewardship that extends beyond patient population differences alone. The observed reduction in prescribing over the study period is encouraging and suggests growing awareness of fluoroquinolone safety concerns. To consolidate this trend, we recommend structured prescriber education targeting MHRA fluoroquinolone guidance and appropriate alternative agents, and a re-audit to evaluate whether these interventions result in sustained reductions in ciprofloxacin use across both sites.